Recombinant anti-PD-L1/TGF-β bifunctional fusion protein
重组抗PD-L1和TGF-β双功能融合蛋白
Report date: 2026/04/16 20:00:17
Base Information
Drug NameRecombinant anti-PD-L1/TGF-β bifunctional fusion protein
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHualan Genetic Engineering (Henan) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A